JPRN-jRCTc040190130已完成2 期
Randomized phase II study with or without adjuvant immunotherapy of alpha-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer - Randomized phase II of adjuvant immunotherapy using alpha-GalCer-pulsed dendritic cells in completely resected stage II-IIIA non-small cell lung cancer (RADCLC)
Saka Hideo0 个研究点目标入组 57 人开始时间: 2020年3月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 57
研究概览
简要总结
Although it was suggested that the safety of intravenous administration of GalCer pulsed dendritic cells aiming at activation of NKT cells in the body as immunotherapy using NKT cells is high, "No recurrence in the NKT cell therapy group and the standard treatment group" The null hypothesis that "survival times are equal" could not be denied.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1) Patients for whom non-small cell lung cancer is confirmed histologically
- •2) Patients underwent at least lung lobectomy including elective or non-elective dissection of hilar or mediastinal lymph node
- •3) Complete resection is judged (Complete resection is defined to be the situation that tumor is completely removed grossly at the time of operation and tumor cells are not noted pathologically on the resection line.)
- •4) The pathological stage is IIA, IIB, IIIA.
- •5) At the time of enrollment, patients should be at least 20 years old and younger than 75 years old.
- •6) no recurrence at the time of enrollment
- •7) PS (ECOG; Eastern Cooperative Oncology Group) is 0-1.
- •8) Trial treatment can be started within 4 to 16 weeks after 3-4 cycles of adjuvant chemotherapy with cisplatin and vinorelbine.
- •9) Functions of the bone marrow, liver, kidney, and lung etc are maintained, satisfying the following conditions. (The following data should be the ones within 2 weeks before enrollment. The same day of the week 2 weeks before enrollment can be included.)
- •*Neutrophil count >=3,000/mm3
- •*Platelet count >=75,000/mm3
- •*Hemoglobin concentration>=9 g/dL
- •*Serum creatinine <=1.5 mg/dL
- •*Total bilirubin <=2.0 mg/dL
- •*AST/ALT <=2.0 X ULN of normal values in each institution
- •*SpO2 >=93%
- •10) NKT cells are detected at least 10 cells in 1 ml of peripheral blood.
- •11) After the details of the trial are explained sufficiently before enrollment in this trial, written consent by patients themselves should be obtained.
排除标准
- •1) Serious concomitant disease including severe infectious disease or malnutrition.
- •2) Postoperative pleural effusion or ascites or cardiac effusion which need to be controlled.
- •3) The patient who have simultaneous malignancy or who have metachronous malignancy within 5 years-disease free interval.
- •4) Concurrent corticosteroid therapy
- •5)Autoimmune disease
- •6) History of hepatitis
- •7) Positive response to HIV, hepatitis C virus or human T cell lymphotrophic virus antibodies or those with HBs antigen.
- •8) Severe cardiac disease(NYHA class III or IV) or severe pulmonary disease (greater than Hugh-Jones Classification III)
- •9) History of hyper-reactivity to albmin
- •10) Pregnancy or lactation
- •11) Contraindication to apheresis (angina, greater than atrioventricular block 2 degree, WPW syndrome, complete left bundle branch block, systolic blood pressure with 90 Torr or greater than 170 Torr)
- •12) The patients have been judged to be inappropriate to participate in this study by principal investigator.
研究者
相似试验
已完成
2 期
An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 InfectionHIV-1NCT00074997Janssen-Cilag Pty Ltd1
招募中
2 期
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) PatientsST Elevation Myocardial InfarctionNCT06147986Ever Supreme Bio Technology Co., Ltd.41
Unknown
2 期
Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLCNon Small Cell Lung CancerNCT02669719Shanghai Chest Hospital70
Unknown
1 期
A Pilot Study of FFP104 in Subjects With Crohn's DiseaseCrohn's DiseaseNCT02465944Fast Forward Pharmaceuticals24
已完成
1 期
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy AdultsMeningococcal VaccinesNCT02810340PATH60